TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Price, Quote, News and Overview
NASDAQ:TCBP - Nasdaq - US87807D5095 - ADR - Currency: USD
TCBP Quote, Performance and Key Statistics
2.5
-0.12 (-4.58%)
The current stock price of TCBP is 2.5 USD. In the past month the price decreased by -64.29%. In the past year, price decreased by -98.51%.
TCBP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About TCBP
Company Profile
TC Biopharm (Holdings) PLC is a GB-based company operating in Biotechnology industry. The company employs 41 full-time employees The company went IPO on 2022-02-23. TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies (GD-Ts) for the treatment of cancer with human efficacy data in acute myeloid leukemia. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Company Info
TC BIOPHARM HOLDINGS PLC-ADR
Maxim 1, 2 Parklands Way, Holytown
Honiton GB
Employees: 41
Company Website: https://www.tcbiopharm.com
Investor Relations: https://www.tcbiopharm.com/news/press-releases
Phone: 441414337557
TC BIOPHARM HOLDINGS PLC-ADR / TCBP FAQ
What is the stock price of TC BIOPHARM HOLDINGS PLC-ADR today?
The current stock price of TCBP is 2.5 USD. The price decreased by -4.58% in the last trading session.
What is the ticker symbol for TC BIOPHARM HOLDINGS PLC-ADR stock?
The exchange symbol of TC BIOPHARM HOLDINGS PLC-ADR is TCBP and it is listed on the Nasdaq exchange.
On which exchange is TCBP stock listed?
TCBP stock is listed on the Nasdaq exchange.
What is TC BIOPHARM HOLDINGS PLC-ADR worth?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) has a market capitalization of 25.65M USD. This makes TCBP a Nano Cap stock.
How many employees does TC BIOPHARM HOLDINGS PLC-ADR have?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) currently has 41 employees.
What are the support and resistance levels for TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) has a resistance level at 2.63. Check the full technical report for a detailed analysis of TCBP support and resistance levels.
Is TC BIOPHARM HOLDINGS PLC-ADR (TCBP) expected to grow?
The Revenue of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TCBP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TCBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TCBP, evaluating the profitability, health, valuation and growth aspects
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Sales and EPS estimates to see what analysts future expectations are.
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Chart to make your own analysis
- TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Latest news and press-releases to stay up to date.
Does TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock pay dividends?
TCBP does not pay a dividend.
When does TC BIOPHARM HOLDINGS PLC-ADR (TCBP) report earnings?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) will report earnings on 2022-12-13, before the market open.
What is the Price/Earnings (PE) ratio of TC BIOPHARM HOLDINGS PLC-ADR (TCBP)?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).
TCBP Technical Analysis
TCBP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TCBP. TCBP may be in some trouble as it scores bad on both profitability and health.
TCBP Financial Highlights
Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS decreased by -1265.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| Debt/Equity | 1.07 |
TCBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TCBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP